US.MRK · Merck & Co.

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 2.6190309847950393,
        "turnoverUsdM": 1077.10713824211,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.MRK",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 137.13,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.2,
      "take_profit_price": 151.9455,
      "target_multiplier": 1.6,
      "technical_strength": 1.38,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.2380619695900785,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 43.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 42.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 1
  },
  "market": {
    "ma20": 147.35,
    "ma50": 135.6728,
    "close": 144.71,
    "prevClose": 147.53,
    "avgVolume20": 11088331,
    "volumeRatio": 0.67,
    "changePercent": -1.91
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 1,
    "details": {
      "ret_5d": -0.045700276971775144,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 1,
      "vcp_bonus": 0,
      "vol_ratio": 0.6622942957372076,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.0866545467519624,
      "volat_points": 0,
      "day_range_pct": 0.02667403588735854,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 43.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 5.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 36,
        "contribution": 5.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 17.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 58.33,
        "contribution": 17.5
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 42.9,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 5.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 17.5/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.2,
      "資金流": 6.8,
      "市場環境": 5.4,
      "情緒分析": 2,
      "技術信號": 17.5,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 1077.10713824211,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 0.8,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRK",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.52749955,
                "ma50": 710.6121986999997,
                "name": "QQQ",
                "close": 708.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 767.5584954500001,
                "ma50": 758.2458016200002,
                "name": "SPY",
                "close": 757.83002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.6190309847950393,
          "atrPoints": 3,
          "cciPoints": 1.6,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142066203,
                "url": "https://finnhub.io/api/news?id=82d4994d91fdd80a460935678d97a2d7176f3832d1c607a4401e58380e9be46f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the most recent trading session, Merck (MRK) closed at $144.71, indicating a -1.91% shift from the previous trading day.",
                "category": "company",
                "datetime": 1789077004,
                "headline": "Merck (MRK) Dips More Than Broader Market: What You Should Know"
              },
              {
                "id": 142060792,
                "url": "https://finnhub.io/api/news?id=729954b3edddc9fa048f800ac7f49b5c1f712ff9ba32babbdb9b5a5c7768a621",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1789045205,
                "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 142029535,
                "url": "https://finnhub.io/api/news?id=ab9f063581451abab226bae361bb571608d0d3d60f3a1cb25b6582f0302750a7",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (MRK) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsCaroline Litchfield - Executive...",
                "category": "company",
                "datetime": 1788974228,
                "headline": "Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141464532,
                "url": "https://finnhub.io/api/news?id=859ae5880b7c332a700086755ffd836f615a8ae3befc592be9cb64449c091135",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.",
                "category": "company",
                "datetime": 1788558302,
                "headline": "Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 141444057,
                "url": "https://finnhub.io/api/news?id=b7fbc72be00a293e3df05b3d90005d43560f1c1c155fdf0a63c6ff2f0f514209",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received FDA approval for LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor for hypercholesterolemia. The new therapy offers a pill-based alternative to existing injectable PCSK9 treatments for patients with high cholesterol. The approval introduces a new segment in cholesterol management that other drug companies are also targeting with oral PCSK9 candidates. For a broader view of where drug development and data driven medicine intersect, explore other healthcare...",
                "category": "company",
                "datetime": 1788541761,
                "headline": "Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?"
              },
              {
                "id": 141400382,
                "url": "https://finnhub.io/api/news?id=8705547ad79d5ce30f69edff8b117985fe7193bc87ac7ad4d4573de2ed3766c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449419,
                "headline": "Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?"
              },
              {
                "id": 141373098,
                "url": "https://finnhub.io/api/news?id=3b8ae9abd0431d10053f8279b998a980036723c7d887184dd5f43c60a6006a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer...",
                "category": "company",
                "datetime": 1788311942,
                "headline": "Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat?"
              },
              {
                "id": 141361107,
                "url": "https://finnhub.io/api/news?id=604a74c67cc76ee833e91a11b652ccba9c35816d3796c281b4852b3f31915326",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) and Moderna report the first positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients. The therapy was tested in combination with Merck's immunotherapy KEYTRUDA in a Phase 3 trial setting. This marks the first time an mRNA-based individualized neoantigen approach has shown clinically meaningful and statistically significant Phase 3 data in cancer. The result signals a potential new path for personalized cancer vaccines with...",
                "category": "company",
                "datetime": 1788095722,
                "headline": "Merck (MRK) Posts First Positive Phase 3 Result For Personalized mRNA Melanoma Therapy"
              }
            ],
            "raw_source": [
              {
                "id": 142066203,
                "url": "https://finnhub.io/api/news?id=82d4994d91fdd80a460935678d97a2d7176f3832d1c607a4401e58380e9be46f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the most recent trading session, Merck (MRK) closed at $144.71, indicating a -1.91% shift from the previous trading day.",
                "category": "company",
                "datetime": 1789077004,
                "headline": "Merck (MRK) Dips More Than Broader Market: What You Should Know"
              },
              {
                "id": 142064745,
                "url": "https://finnhub.io/api/news?id=ec7e31288ec30d3ed445c243aaa5470eb1ec4dfe7aa9137eda86ec50309ce44d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.",
                "category": "company",
                "datetime": 1789067434,
                "headline": "Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?"
              },
              {
                "id": 142064394,
                "url": "https://finnhub.io/api/news?id=adf9fabb65fa1bdc0746c8cf7941b566bd25d62715d8b6fa00e9d6a2953470bc",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1789067407,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 142064746,
                "url": "https://finnhub.io/api/news?id=1abe8e7dab24ae7989315403c7be9a89f24836f0d543d8d14ac5a49793d3b96e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.",
                "category": "company",
                "datetime": 1789063054,
                "headline": "JNJ Stock: Is the Rally Running Out of Steam?"
              },
              {
                "id": 142063291,
                "url": "https://finnhub.io/api/news?id=45a4c767641875677341490c5c57df95988778e7db0af9183d8a84bc58b8398b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.",
                "category": "company",
                "datetime": 1789059954,
                "headline": "Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?"
              },
              {
                "id": 142062621,
                "url": "https://finnhub.io/api/news?id=3c6dd7e37edbe2d02b33bc261a6730d798fa99bd613b91d01d5e24dda6b86b3d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Thursday.",
                "category": "company",
                "datetime": 1789058407,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 142063283,
                "url": "https://finnhub.io/api/news?id=65f0ac67eae27fb2191dd56e7eb745fccf116fdc0af9a920181fbeed1f583b13",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.",
                "category": "company",
                "datetime": 1789058116,
                "headline": "Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?"
              },
              {
                "id": 142061927,
                "url": "https://finnhub.io/api/news?id=77708395cb873f8e8de1feb66a6d4b96bea1392d39ff1c5ec9ba92ca08be0a88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.",
                "category": "company",
                "datetime": 1789054500,
                "headline": "GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff"
              },
              {
                "id": 142061785,
                "url": "https://finnhub.io/api/news?id=319f28aeaea63b63ec1d3933aeb670aebb9c5465de023eaec04e187f46e57e89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.",
                "category": "company",
                "datetime": 1789052702,
                "headline": "Why Has AbbVie Gone Quiet About Humira?"
              },
              {
                "id": 142061929,
                "url": "https://finnhub.io/api/news?id=43458b60b2e94321812dc11320e682a658d20671e047fdbb7076f0a930b46488",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.",
                "category": "company",
                "datetime": 1789052580,
                "headline": "Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?"
              },
              {
                "id": 142063327,
                "url": "https://finnhub.io/api/news?id=d04a62e1ad2172459477f0d878262bfbf3b2b6a32affc0ad595cc90ca30776ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Health policy analysts are raising concerns about the rising cost of Medicare’s prescription drug program after more than 1 in 5 Medicare Part D enrollees hit the program’s $2,000 out-of-pocket drug cap in 2025. The finding, included in a report...",
                "category": "company",
                "datetime": 1789052438,
                "headline": "Medicare’s $2,000 Drug Cap Is Getting Expensive — More Than 1 in 5 Seniors Hit It as Drug Spending Heads Toward $346 Billion"
              },
              {
                "id": 142060792,
                "url": "https://finnhub.io/api/news?id=729954b3edddc9fa048f800ac7f49b5c1f712ff9ba32babbdb9b5a5c7768a621",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1789045205,
                "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 142059579,
                "url": "https://finnhub.io/api/news?id=a6c317b3e460abcacb3902f7a31911d01e805adf26ba1281143dd2267c765d58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The role will focus on identifying new opportunities and strengthening existing customer relationships to accelerate Ritedose’s continued growthCOLUMBIA, S.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose), the largest contract development and manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit-dose solutions for the ophthalmic and respiratory markets, today announced the appointment of Carolyn Berg as th",
                "category": "company",
                "datetime": 1789040220,
                "headline": "Ritedose Appoints Carolyn Berg as New Vice President of Strategic Growth"
              },
              {
                "id": 142062544,
                "url": "https://finnhub.io/api/news?id=c635754bf641453601db306335d6d6ee43a95105341bf85ef2a6fb7d0e02b5e3",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "September 9, 2026 records indicate that Representative Maria Elvira Salazar filed a purchase of Merck & Co (NYSE:MRK), valued between $34,006 and $160,000. According to the September filing, the transaction occurred",
                "category": "company",
                "datetime": 1789038030,
                "headline": "Recent Filing Shows That Rep. Maria Elvira Salazar Bought Over $34K Worth of Merck & Co Stock"
              },
              {
                "id": 142062545,
                "url": "https://finnhub.io/api/news?id=d93413a0c15fc691f6abcde0de8ab19811061780ea28c87ce78c53cbf316f4dc",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "HSBC  analyst Rajesh Kumar   maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $150 to $172.",
                "category": "company",
                "datetime": 1789033321,
                "headline": "HSBC Maintains Buy on Merck & Co, Raises Price Target to $172"
              },
              {
                "id": 142060793,
                "url": "https://finnhub.io/api/news?id=501b1bfa2a396fea7bf6a4009d23874fce74b44d31e36558453bdad953889fd4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.",
                "category": "company",
                "datetime": 1789031853,
                "headline": "mRNA cancer vaccines’ biggest barriers to market"
              },
              {
                "id": 142048468,
                "url": "https://finnhub.io/api/news?id=5915846a89f7a05f7e6ee9b7116407801a68d45a437cbe7d6a367e938e0e0033",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (NYSE:MRK) executives outlined a strategy centered on pipeline investment, new product launches and targeted business development as the company prepares for the eventual loss of exclusivity for KEYTRUDA. Chief Financial Officer Caroline Litchfield said Merck has increased its est",
                "category": "company",
                "datetime": 1789027324,
                "headline": "Merck Targets $70B Pipeline as It Prepares for KEYTRUDA Exclusivity Loss"
              },
              {
                "id": 142048040,
                "url": "https://finnhub.io/api/news?id=52562ddf2a6c2687841344a20584b7dbbff017f24bdf5eb5c9ae273fdb14f613",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221231962/image_2221231962.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating.",
                "category": "company",
                "datetime": 1789012200,
                "headline": "AI And Robotics In 2026: 16 Recent Developments For Investors"
              },
              {
                "id": 142037821,
                "url": "https://finnhub.io/api/news?id=111db1e73b95e44821420ce4a7307dd477cbd22ec124737b00e8ef9d99e156e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.",
                "category": "company",
                "datetime": 1789007538,
                "headline": "Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes"
              },
              {
                "id": 142029776,
                "url": "https://finnhub.io/api/news?id=d0731908caf2bd1afebdf178ac483ad1e6acebd96431ddace79e6a6f8dcaac48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.",
                "category": "company",
                "datetime": 1788986503,
                "headline": "What Eli Lilly Was Telling You While It Rationed Its Own Launches"
              },
              {
                "id": 142028236,
                "url": "https://finnhub.io/api/news?id=3f9396fd378945ab289f1fef5df0f06f15cd8f5cea04f043344d77ae53f1a0a4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1788981004,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 142029535,
                "url": "https://finnhub.io/api/news?id=ab9f063581451abab226bae361bb571608d0d3d60f3a1cb25b6582f0302750a7",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. (MRK) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsCaroline Litchfield - Executive...",
                "category": "company",
                "datetime": 1788974228,
                "headline": "Merck & Co., Inc. (MRK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 142025946,
                "url": "https://finnhub.io/api/news?id=260787e40763554b599e538d2925e0226176405665e413d8226053bb7d1fd260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Oracle, Merck and Union Pacific headline fresh research, while microcaps CVD Equipment and Koil Energy show strong gains with distinct growth drivers.",
                "category": "company",
                "datetime": 1788964020,
                "headline": "The Zacks Analyst Blog Highlights Oracle, Merck, Union Pacific, CVD Equipment and Koil Energy Solutions"
              },
              {
                "id": 142026820,
                "url": "https://finnhub.io/api/news?id=8b0260feb9fcb3d808bd80def718c92efdb6b0332525b5c181772180baf2e750",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404205960/image_1404205960.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Absci is rated SELL, as its valuation is highly concentrated on ABS-201 with limited partner revenue and an early-stage pipeline. Click for more on ABSI.",
                "category": "company",
                "datetime": 1788959272,
                "headline": "Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up"
              },
              {
                "id": 142027129,
                "url": "https://finnhub.io/api/news?id=7b9872d99f13714aa23da2aa9888679c965f6cc269ca51eaa5b0c87740cf38f6",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Leerink Partners  analyst Daina Graybosch   maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $127 to $161.",
                "category": "company",
                "datetime": 1788955381,
                "headline": "Leerink Partners Maintains Outperform on Merck & Co, Raises Price Target to $161"
              },
              {
                "id": 142025945,
                "url": "https://finnhub.io/api/news?id=8e32170639ff0e7bd3b839b8b729b6dbc8c91ba80384cf5c81997119737f02f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda patent cliff.",
                "category": "company",
                "datetime": 1788947324,
                "headline": "Merck pairs ADCs with Keytruda in women’s cancer push"
              },
              {
                "id": 141991628,
                "url": "https://finnhub.io/api/news?id=b0c60380221bf68b6b62d8e0691fda4ba0456fc7e91bb5fbf67c3d0df07368f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "178-Page Report Tracks Merck's Cidara Buyout and CD388's Phase 3 Launch as Roche, Moderna, and GSK Compete Beyond the Vaccine Status QuoDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The \"Influenza a Infections - Market Insight, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. A new \"Influenza A - Market Insights, Epidemiology, and Market Forecast - 2036\" report provides a comprehensive analysis of the Influenza A market across the United States, EU4 cou",
                "category": "company",
                "datetime": 1788941220,
                "headline": "Influenza A Market Insight, Epidemiology, and Market Forecast - 2036 Now Available — See Why a 70% Vaccine Failure Rate Is Fueling the Race for Next-Gen Flu Therapies"
              },
              {
                "id": 142023862,
                "url": "https://finnhub.io/api/news?id=11fd80725570f8c725693b9b19b81a17ee99e6102f0085df9eb27e7c4d33d9cf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.",
                "category": "company",
                "datetime": 1788937200,
                "headline": "A new immuno-oncology play raises $225M for a next-generation drug"
              },
              {
                "id": 141956234,
                "url": "https://finnhub.io/api/news?id=2a1a523fa8cdd81f0e5a709a42b251d610672c211deec6586755e1992960d0f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Oracle, Merck and Union Pacific lead today's stock reports, with cloud growth, drug sales and rail strength driving their investment stories.",
                "category": "company",
                "datetime": 1788909180,
                "headline": "Top Stock Reports for Oracle, Merck & Union Pacific"
              },
              {
                "id": 141958756,
                "url": "https://finnhub.io/api/news?id=aa5a8dae82f13a09da7b7747ff3e432b7d63e751a7aae9c5efd207e98bc27ce7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1788900913,
                "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2026 Update"
              },
              {
                "id": 141952570,
                "url": "https://finnhub.io/api/news?id=5705e6aac332197632f6883717364f774adac3cf64f03b6da96a17c69f795736",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.",
                "category": "company",
                "datetime": 1788887331,
                "headline": "Is AbbVie Stock Too Reliant On Skyrizi?"
              },
              {
                "id": 142025247,
                "url": "https://finnhub.io/api/news?id=8987b9aafbb61dc6d9ec52cbf383b6c49aa3d2df3eb7ee6b70cb6a541d1025c7",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.bloomberg.com/news/articles/2026-09-08/fda-s-acting-drug-vaccine-regulators-tapped-for-permanent-roles",
                "category": "company",
                "datetime": 1788884454,
                "headline": "'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg"
              },
              {
                "id": 141950162,
                "url": "https://finnhub.io/api/news?id=70423431bc7b150e3630ade48f615f5dd07d0c36f4e85b7c28b19b44f9016e98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.",
                "category": "company",
                "datetime": 1788878400,
                "headline": "MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?"
              },
              {
                "id": 141949985,
                "url": "https://finnhub.io/api/news?id=23e22eca29f124149162f38fb98cc7d4fd8a268c0cb690d6bdce0f160f07e68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.",
                "category": "company",
                "datetime": 1788878194,
                "headline": "What Merck Stopped Saying About GARDASIL Should Change What You Watch"
              },
              {
                "id": 141950156,
                "url": "https://finnhub.io/api/news?id=42df889edd57ef233368d6f8698eadbc5aa569a477a9fd479aacbb24ee6aec58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.",
                "category": "company",
                "datetime": 1788871080,
                "headline": "Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?"
              },
              {
                "id": 141950157,
                "url": "https://finnhub.io/api/news?id=7818a94b5d1882d790a212e39790daa1ada2f2888ae4c8de1c6bc22fa2dafa8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-executive director. Dr. Cannon brings more than 30 years of commercial leadership experience in the biopharmaceutical industry, particularly at Merck and Roivant Sciences. During more than 25 years at Merck, she held senior commercial roles including Global Com",
                "category": "company",
                "datetime": 1788868800,
                "headline": "Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director"
              },
              {
                "id": 141953315,
                "url": "https://finnhub.io/api/news?id=2356be14a57c01489021eb545d17f19625904eb61bcb0c3e797acc2312a23418",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Cancer---Heart-Shape-To-Represent-Medica.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.",
                "category": "company",
                "datetime": 1788866963,
                "headline": "Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates"
              },
              {
                "id": 141951906,
                "url": "https://finnhub.io/api/news?id=8516a4e5e27068b7c69780eccea33f98d398d6703fa4e598ec89e1e4baf85c7b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/08/Eli-Lilly-And-Company-Logo-On-Dark-Backg.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.",
                "category": "company",
                "datetime": 1788866855,
                "headline": "Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back"
              },
              {
                "id": 141950158,
                "url": "https://finnhub.io/api/news?id=423cc2edb18f28a7cfc21f733c16c3c06840dfad2096212e99763a4d877922bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., September 08, 2026--Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference",
                "category": "company",
                "datetime": 1788864300,
                "headline": "Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference"
              },
              {
                "id": 141949322,
                "url": "https://finnhub.io/api/news?id=4327394c95660a20d019c67d42085de8642f275075d61e1337f760a5b7bc2062",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2285918278/image_2285918278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "NewAmsterdam Pharma (NAMS) has seen a near 40% stock pullback post-Merck’s Lipfendra approval, but retains multi-blockbuster potential with obicetrapib. Read the latest on the stock here.",
                "category": "company",
                "datetime": 1788862119,
                "headline": "NewAmsterdam Pharma: Potential Coupled With Uncertainty"
              },
              {
                "id": 141954354,
                "url": "https://finnhub.io/api/news?id=819a92d997994b630d6e33f8f6bec3304ec52174db4a013ccf3cb1a51538a42b",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $146 to $170.",
                "category": "company",
                "datetime": 1788860314,
                "headline": "Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $170"
              },
              {
                "id": 141868205,
                "url": "https://finnhub.io/api/news?id=fcfa5e246cc835c64f0d7b5ddb14a2a1a880c36572c3dc06c22aeb5a62e5d566",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hypertension (PAH) market across the United States, EU4 countries-Germany, France, Italy, and Spain-the United Kingdom, and Japan reached approximately USD 8 billion in 2025. The market is projected to expand at a compound annual growth rate of 6.7% from 2022 to 2036, supported by ri",
                "category": "company",
                "datetime": 1788856260,
                "headline": "Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio"
              },
              {
                "id": 141950160,
                "url": "https://finnhub.io/api/news?id=ed6e379c5f72322b5d9d309f96e6f633a8dde6088c2625b5e625dd5510bf205f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The Hashgraph Group (THG) and science and technology company Merck, are piloting a cocoa traceability solution, with PwC Germany providing consulting and implementation support. The solution connects physical product authentication with blockchain-based digital records and enterprise process design.",
                "category": "company",
                "datetime": 1788850800,
                "headline": "The Hashgraph Group and Merck with support from PwC Germany develop solution for cocoa traceability and digital product passports"
              },
              {
                "id": 141787034,
                "url": "https://finnhub.io/api/news?id=28056929daf7e863fdaa2b0207034941eafc3b574c601e0a07547ac1dadb006a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.",
                "category": "company",
                "datetime": 1788832154,
                "headline": "The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI"
              },
              {
                "id": 141771129,
                "url": "https://finnhub.io/api/news?id=8d4ddd4505d0a2c0a565fc6aa50cad54667e4793873643445d02cbd7344ed953",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.",
                "category": "company",
                "datetime": 1788800445,
                "headline": "Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now"
              },
              {
                "id": 141771109,
                "url": "https://finnhub.io/api/news?id=29beab0809a7c2bc4164cb099588839029845495068a3c91385c65a59211c3d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Emerging therapies for ulcerative colitis treatment, such as Obefazimod (Abivax), Tulisokibart (Merck), Olamkicept (Ferring Pharmaceuticals), Afimkibart (Roche), Icotrokinra (Johnson & Johnson/Protagonist Therapeutics), Duvakitug (Teva Pharmaceuticals/Sanofi), Zotemtegrast (Eli Lilly), Zasocitinib (Takeda), XmAb942 (Xencor), and others, reflect a growing ulcerative colitis market, advancing novel mechanisms to address unmet needs in moderate-to-severe disease.New York, USA, Sept. 07, 2026 (GLOBE",
                "category": "company",
                "datetime": 1788800400,
                "headline": "Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight"
              },
              {
                "id": 141760935,
                "url": "https://finnhub.io/api/news?id=9f51313c5b3c77384d06c621b598127ced700b1ca8ebed5cb5ba133ec949c83a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035\" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans",
                "category": "company",
                "datetime": 1788778920,
                "headline": "Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva"
              },
              {
                "id": 141762536,
                "url": "https://finnhub.io/api/news?id=755171ce4130cab475d6d9e4eb412f6569c568e60203dffab6ff579c86acade5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.",
                "category": "company",
                "datetime": 1788699000,
                "headline": "Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It"
              },
              {
                "id": 141491619,
                "url": "https://finnhub.io/api/news?id=c3748497894521a11c661f28144f376bd12e723c1080964e7ff112ad03c70ae4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1391545555/image_1391545555.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "With the lagging performance aside, there have been some notable big winners among the index's 30 components. Read more here.",
                "category": "company",
                "datetime": 1788568200,
                "headline": "Nike: Just Not Doing It"
              },
              {
                "id": 141464532,
                "url": "https://finnhub.io/api/news?id=859ae5880b7c332a700086755ffd836f615a8ae3befc592be9cb64449c091135",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.",
                "category": "company",
                "datetime": 1788558302,
                "headline": "Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 141452825,
                "url": "https://finnhub.io/api/news?id=112e1e8978d52d2cbd5db13911f01181162e86289295dc3706f8a282f6894de5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1788549006,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 141532987,
                "url": "https://finnhub.io/api/news?id=0b2e80aba0b3d7d5fe39a3ddb8053ff207155ae9867f3aa9a29972071b2862fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.",
                "category": "company",
                "datetime": 1788542100,
                "headline": "Revolution Medicines Got Its Breakthrough—What Moves It Next?"
              },
              {
                "id": 141444057,
                "url": "https://finnhub.io/api/news?id=b7fbc72be00a293e3df05b3d90005d43560f1c1c155fdf0a63c6ff2f0f514209",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) received FDA approval for LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor for hypercholesterolemia. The new therapy offers a pill-based alternative to existing injectable PCSK9 treatments for patients with high cholesterol. The approval introduces a new segment in cholesterol management that other drug companies are also targeting with oral PCSK9 candidates. For a broader view of where drug development and data driven medicine intersect, explore other healthcare...",
                "category": "company",
                "datetime": 1788541761,
                "headline": "Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?"
              },
              {
                "id": 141444058,
                "url": "https://finnhub.io/api/news?id=905919b186b2cb70f624aa1750860bd8a239d54c5d4daa0db9581cc8254fae21",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.",
                "category": "company",
                "datetime": 1788541047,
                "headline": "Was JNJ Stock Rally Actually Its Own?"
              },
              {
                "id": 141437305,
                "url": "https://finnhub.io/api/news?id=0c93ddd9be3d327abe99db231fe5877cde8ee6c7727910681b0e469d3573b4d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.",
                "category": "company",
                "datetime": 1788532620,
                "headline": "SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China"
              },
              {
                "id": 141446169,
                "url": "https://finnhub.io/api/news?id=a28c7b57bba478810aa433755c68562b12542576c05229386dec146815ecae11",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $170.",
                "category": "company",
                "datetime": 1788517672,
                "headline": "Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $170"
              },
              {
                "id": 141405291,
                "url": "https://finnhub.io/api/news?id=8c38270c7e5423e3afbf1e2a7d23c244a349d8d8d10eff1cc1f97e9ecfaceee5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Cipla secured exclusive U.S. commercialization rights to Qilu's proposed biosimilar ahead of Keytruda's expected 2028 patent expiration.",
                "category": "company",
                "datetime": 1788470854,
                "headline": "Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning"
              },
              {
                "id": 141405292,
                "url": "https://finnhub.io/api/news?id=21cfe36b3ec755a99e784bc55dd2dcc02a60b56fc6f524b5661bee05417821eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "LAKE ZURICH, Ill., September 03, 2026--Fresenius Kabi, a global healthcare company part of the Fresenius Group, specializing in lifesaving therapies and technologies, today announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Exclusivity for the branded medicine Bridion® (Merck) expired in July 2026.",
                "category": "company",
                "datetime": 1788469200,
                "headline": "Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S."
              },
              {
                "id": 141403790,
                "url": "https://finnhub.io/api/news?id=1548687fecf537e8e4484d6edea21ed97a99feddaf4fd5587f4cad353faadd83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.",
                "category": "company",
                "datetime": 1788457140,
                "headline": "Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense"
              },
              {
                "id": 141402789,
                "url": "https://finnhub.io/api/news?id=fe73ec7a4abefa0321761190f458da536ef1723709c1600d1270ee69f26c1e56",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.",
                "category": "company",
                "datetime": 1788456587,
                "headline": "Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold"
              },
              {
                "id": 141401625,
                "url": "https://finnhub.io/api/news?id=7f9aedd8a41fb14ffcc587468eac74b7ff6e8786ce888f5fb9c434afbabf0e5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.",
                "category": "company",
                "datetime": 1788456240,
                "headline": "Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?"
              },
              {
                "id": 141401562,
                "url": "https://finnhub.io/api/news?id=1f94100c220d7a64393c01745fc80348758aa2c70eaf3e505da0a90106a9fa2b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.",
                "category": "company",
                "datetime": 1788455269,
                "headline": "Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?"
              },
              {
                "id": 141401623,
                "url": "https://finnhub.io/api/news?id=571938922c53a24695a79bd4b7bcf6cadc277e382964d905e6dd29c162da8113",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.",
                "category": "company",
                "datetime": 1788454800,
                "headline": "Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug"
              },
              {
                "id": 141401563,
                "url": "https://finnhub.io/api/news?id=50bde06ec4383c3e8fc1744e10def00da142de1f05932785daae894c39691680",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.",
                "category": "company",
                "datetime": 1788454466,
                "headline": "ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?"
              },
              {
                "id": 141401283,
                "url": "https://finnhub.io/api/news?id=143eae70bc52137eaf641d1530c12a1dc1498df8ded75872f63b9e22f8933c67",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Thursday.",
                "category": "company",
                "datetime": 1788453607,
                "headline": "Discover which dow jones stocks are making waves on Thursday."
              },
              {
                "id": 141400382,
                "url": "https://finnhub.io/api/news?id=8705547ad79d5ce30f69edff8b117985fe7193bc87ac7ad4d4573de2ed3766c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788449419,
                "headline": "Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?"
              },
              {
                "id": 141400340,
                "url": "https://finnhub.io/api/news?id=d605837c09a466bf298019b4b1f79af8743705ece69897637d710b520f1b2b7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.",
                "category": "company",
                "datetime": 1788449092,
                "headline": "Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?"
              },
              {
                "id": 141400381,
                "url": "https://finnhub.io/api/news?id=adeb5e4b160bfa4c1f7b5e497c2d42856d151be4b132e391f5aa87e4415edece",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.",
                "category": "company",
                "datetime": 1788448560,
                "headline": "Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop"
              },
              {
                "id": 141400341,
                "url": "https://finnhub.io/api/news?id=ad022e5bc8dde3e4d944411bba52005d8a98c7c6847a875884ffee4bfc31fea2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.",
                "category": "company",
                "datetime": 1788448140,
                "headline": "Pfizer's Pipeline Strategy Centers on Obesity and Oncology"
              },
              {
                "id": 141403192,
                "url": "https://finnhub.io/api/news?id=222861cbe182e09bd124e5448a1086f89de7650eb4bc2e208436fb5e5363a845",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193840462/image_2193840462.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "As legacy pharmaceutical models face structural challenges, targeting the underlying technology enablers of next-generation care offers a compelling approach for healthcare investors.",
                "category": "company",
                "datetime": 1788444600,
                "headline": "Why Moderna's Cancer Vaccine Matters To Investors"
              },
              {
                "id": 141401187,
                "url": "https://finnhub.io/api/news?id=cc8b651391ba31db3beab971f70b7bb7d2b28c96e9c54b76c55af30bb5547411",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/03/Konskie--Poland---December-08--2024-Summ.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in a Phase 3 lung cancer clinical trial.",
                "category": "company",
                "datetime": 1788433026,
                "headline": "Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study"
              },
              {
                "id": 141399389,
                "url": "https://finnhub.io/api/news?id=f0ccdd9d70fd4474d7861c8c66dc4fe0a697763c33789ba486aea54f04403eeb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310557609/image_1310557609.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "ImmunityBio looks attractive due to ANKTIVA's FDA approval for BCG-unresponsive NMIBC and pipeline expansion potential. See why I rate IBRX stock a Buy.",
                "category": "company",
                "datetime": 1788429250,
                "headline": "ImmunityBio: None Of The Moonshots Is Priced In"
              },
              {
                "id": 141397497,
                "url": "https://finnhub.io/api/news?id=ed1957ad66206400aa38e5738a92e74edc45daa437de09bdc89fa2634ed6800e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1839564383/image_1839564383.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Dogs of the Dow look overvalued, with no must-buy dividend signals.",
                "category": "company",
                "datetime": 1788422137,
                "headline": "Dogs Of The Dow: No Buys And Few Worth Watching"
              },
              {
                "id": 141396877,
                "url": "https://finnhub.io/api/news?id=c79fadb8c7424c24b8db9fce5e390a61f7312a0a55cc2ab006bd9eb2cb5a23c4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2286477227/image_2286477227.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Moderna's upside hinges on Intismeran’s ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.",
                "category": "company",
                "datetime": 1788417365,
                "headline": "Moderna: Massive Asymmetry About What The mRNA Is!"
              },
              {
                "id": 141383190,
                "url": "https://finnhub.io/api/news?id=e182a95e4d7485d608c506c8aecbe8a87907d1a5ebf54cdfe6b70212d13d5007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The real bet is on what lies beyond this year's performance: a pipeline that could change everything.",
                "category": "company",
                "datetime": 1788382536,
                "headline": "Amgen Stock Signals Its Confidence. The Market Agrees."
              },
              {
                "id": 141379513,
                "url": "https://finnhub.io/api/news?id=b83ed80afcb80cbd4652b6ca44f619ec245ce1285bf164a2fe2279ae839bfc54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.",
                "category": "company",
                "datetime": 1788373011,
                "headline": "How Did Merck Stock Beat The Market With Slowing Sales?"
              },
              {
                "id": 141379441,
                "url": "https://finnhub.io/api/news?id=62e773579e3a62df81afcdad4037a0fd886c9dbd055e0ac4c015a53682f0fe97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The market is obsessed with a handful of hyperscalers, but the real story might be the thousands of customers you've never heard of.",
                "category": "company",
                "datetime": 1788369887,
                "headline": "Beyond The Cloud Giants: What Could Power NVIDIA Stock From Here?"
              },
              {
                "id": 141379514,
                "url": "https://finnhub.io/api/news?id=be26bbec50ca5a5b43eebb50858927fd3ecc60fec2a00862e209b8f346cbf49c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.",
                "category": "company",
                "datetime": 1788361800,
                "headline": "AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks"
              },
              {
                "id": 141379511,
                "url": "https://finnhub.io/api/news?id=8780cdd6f1f1fad15e05dfd24f46c854de4ccc02b6ab97af39ced883123d9239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.",
                "category": "company",
                "datetime": 1788361620,
                "headline": "Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?"
              },
              {
                "id": 141376479,
                "url": "https://finnhub.io/api/news?id=2d029860b216fddfbff397866faf68627b7d0e5e085bc67947d73b47a2b94314",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "FINN Partners, one of the world's largest independent communication, public affairs and marketing firms, today announced that Jeffrey L. Sturchio, PhD, is joining as a senior adviser. He will be part of FINN's Global Health Practice and work with the Health Policy and Impact Group. Dr. Sturchio's appointment strengthens a multinational team whose expertise spans health policy, stakeholder engagement, communications and purpose, adding one of global health's most respected advisors to its ranks.",
                "category": "company",
                "datetime": 1788357600,
                "headline": "Global Health Leader Jeffrey L. Sturchio, PhD, Joins FINN Partners' Health Policy and Impact Group as Senior Advisor"
              },
              {
                "id": 141376478,
                "url": "https://finnhub.io/api/news?id=70f5ee04c17fec2fc81eed793a9d35075ea371422f06bbe803a55e67af6db3aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "RAHWAY, N.J., September 02, 2026--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference",
                "category": "company",
                "datetime": 1788349500,
                "headline": "Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference"
              },
              {
                "id": 141373098,
                "url": "https://finnhub.io/api/news?id=3b8ae9abd0431d10053f8279b998a980036723c7d887184dd5f43c60a6006a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer...",
                "category": "company",
                "datetime": 1788311942,
                "headline": "Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat?"
              },
              {
                "id": 141369874,
                "url": "https://finnhub.io/api/news?id=d712d75c450835888382f0049c3dfaaa54fd8760a7b25a62dc9c11038231ace7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.",
                "category": "company",
                "datetime": 1788291120,
                "headline": "Can Bixlenvo Unlock New Growth for Gilead's HIV Business?"
              },
              {
                "id": 141370623,
                "url": "https://finnhub.io/api/news?id=2811d09bc453d60ad535201a16e94c17326b4e0711eab591a46c0c53c4effcac",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Get insights into the dow jones index performance on Tuesday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1788289805,
                "headline": "Stay informed with the top movers within the dow jones index on Tuesday."
              },
              {
                "id": 141369875,
                "url": "https://finnhub.io/api/news?id=25713ea44798b5c5338ef99e3f48cdcdce18c543fa8e5a8f3d3b44d5e44b9a8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.",
                "category": "company",
                "datetime": 1788289217,
                "headline": "Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III"
              },
              {
                "id": 141369876,
                "url": "https://finnhub.io/api/news?id=b4b729cd08099e1154aab3a209d040b8a59a911ae8a6cb3d1379f2bf2e6d31aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.",
                "category": "company",
                "datetime": 1788288240,
                "headline": "Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023."
              },
              {
                "id": 141378635,
                "url": "https://finnhub.io/api/news?id=e4e18d878304530ff690fd40e3e9194a40a530d4efe228b4c517b51541d5d5b2",
                "image": "https://image.cnbcfm.com/api/v1/image/108353953-1787671978491-Traders-20260825-AS-PRESS-7.jpg?v=1787672206&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Stocks rose on Wednesday as U.S. Treasury yields took a breather from the recent run-up that sent them to multiyear highs.",
                "category": "company",
                "datetime": 1788285670,
                "headline": "Stocks rise for first time in four sessions as Treasury yields take breather: Live updates"
              },
              {
                "id": 141368965,
                "url": "https://finnhub.io/api/news?id=c80d53f7cac54342cabbb62192f561e4ee503d10c3a9000331444aeb6824eebf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1788280806,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 141369872,
                "url": "https://finnhub.io/api/news?id=22f605547bfacbaac2c154f62577d8e98379a41e3d1a13b76ad364bcf8dcf597",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "DelveInsight's PCSK9 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Dyslipidemia, Hypercholesterolemia (Familial + Non-Familial), ASCVD, Coronary Revascularization (CABG and PCI), ACS (Acute Myocardial Infarction & Unstable Angina), and others. The selected indications are based on approved therapies and o",
                "category": "company",
                "datetime": 1788276660,
                "headline": "The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight"
              },
              {
                "id": 141369873,
                "url": "https://finnhub.io/api/news?id=1bce6207890c6536b7e9eb485b632e6b759d6d03e2e31443e056c8d59c8c4270",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.",
                "category": "company",
                "datetime": 1788276420,
                "headline": "Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough"
              },
              {
                "id": 141361001,
                "url": "https://finnhub.io/api/news?id=9315fd4dd75780eaab7805f262d6a791796b33062bb781fa99191d618e904bc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock led the index after melanoma vaccine data, while a hedge fund's forced unwind turbocharged a rebound in enterprise software",
                "category": "company",
                "datetime": 1788269873,
                "headline": "S&P 500 biggest August 2026 winners: Moderna, software stocks"
              },
              {
                "id": 141369345,
                "url": "https://finnhub.io/api/news?id=3e8db54c0b5ab5e1fcd7fd29a36003db9ca2ac1882435469d32ca71af62e3594",
                "image": "https://image.cnbcfm.com/api/v1/image/108219605-1761852273367-gettyimages-2243467825-APPLE_EARNS.jpeg?v=1788283461&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Here are some of the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1788269185,
                "headline": "Stocks making the biggest moves midday: Palo Alto Networks, Fervo Energy, Chevron, Apple & more"
              },
              {
                "id": 141361115,
                "url": "https://finnhub.io/api/news?id=5106c7ff5b070fe0c7b6a173a3f38e02b4b2fe6602ed7eebd44bf5318c8e2fe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.",
                "category": "company",
                "datetime": 1788266040,
                "headline": "Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths"
              },
              {
                "id": 141369496,
                "url": "https://finnhub.io/api/news?id=4f91f46ba2696ef86a00fd668abea30ee391a07d5822b5a8219287f5f296dad8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/01/Skin-Cancer-Risk-Remains-High.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.",
                "category": "company",
                "datetime": 1788265512,
                "headline": "Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs"
              },
              {
                "id": 141361110,
                "url": "https://finnhub.io/api/news?id=d5ff30661b36ade78c981291fb8200bfdc2b3593b5b7a0f879ffc1bdf536d503",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.",
                "category": "company",
                "datetime": 1788263097,
                "headline": "Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy"
              },
              {
                "id": 141360400,
                "url": "https://finnhub.io/api/news?id=aa7198b5978cf502913b0190ebe77a269e3448592ea208728fb14c7eaf1f8928",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1788255000,
                "headline": "4 Reasons Why SCHD May Be In A Trouble (Rating Downgrade)"
              },
              {
                "id": 141360369,
                "url": "https://finnhub.io/api/news?id=c1f6f6beede1420f94c162a824c404f259652bdfbddaae165962835edda18e54",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1788254200,
                "headline": "Exelixis: \"Hold\" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data"
              },
              {
                "id": 141361116,
                "url": "https://finnhub.io/api/news?id=00d5e7c3f39d64edeb80638ea6187af7e328a3c5e29fd488b3fc67e6c2ccf850",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The company may be on track to its next product.",
                "category": "company",
                "datetime": 1788253801,
                "headline": "Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?"
              },
              {
                "id": 141361111,
                "url": "https://finnhub.io/api/news?id=84a3369fca40d74a20da124b5e8d22c4b306dc479750442df4f31fc296463d5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in August—making it the highest-gaining stock for the month—driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. It can be recalled that Moderna and Merck recently partnered for […]",
                "category": "company",
                "datetime": 1788245094,
                "headline": "Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally"
              },
              {
                "id": 141361117,
                "url": "https://finnhub.io/api/news?id=6593cd0517ad32cbdb541210175453331bb3059dc150c87637f7d4fc6e86bbc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index.",
                "category": "company",
                "datetime": 1788213900,
                "headline": "There Was No Beating Moderna in August. These Are the Best and Worst S&P 500 Stocks for the Month."
              },
              {
                "id": 141356417,
                "url": "https://finnhub.io/api/news?id=70b9550024f8c5d254fc55828103b4b095d43a0883efa08bacf46c4e37fc2a76",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Get insights into the dow jones index performance on Monday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1788203418,
                "headline": "Top dow jones movers in Monday's session"
              },
              {
                "id": 141369119,
                "url": "https://finnhub.io/api/news?id=a0c7014a0e603d59693dc159665135a67a694ca0ea0155eeaf780b43cad0d380",
                "image": "https://image.cnbcfm.com/api/v1/image/108356724-17882112331788211231-48101579622-1080pnbcnews.jpg?v=1788211232&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Michael Yee, UBS, joins 'Closing Bell Overtime' to talk the state of the biotech and pharmaceutical sectors.",
                "category": "company",
                "datetime": 1788197636,
                "headline": "UBS Michael Yee: We've been quite bullish on the pharma sector"
              },
              {
                "id": 141360884,
                "url": "https://finnhub.io/api/news?id=352ccb9dbc196e7fd72c636ec84aecaf01f3e6b3516908358b7cc115d9b040a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "PFE's oncology growth is led by Padcev, while a broad pipeline and label expansions aim to fuel longer-term gains.",
                "category": "company",
                "datetime": 1788194220,
                "headline": "From Padcev to PF-08634404: Pfizer's Oncology Growth Push"
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141356002,
                "url": "https://finnhub.io/api/news?id=e31bb94ba8ba5bf570eec0910d8d4a76f8de5cb1337c82447b88712cea7dea53",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2266615986/image_2266615986.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "After outperforming its benchmark in 1Q2026, the Nomura Value Fund Institutional Class shares lost considerable ground to the Russell 1000® Value Index in 2Q2026. Read more here.",
                "category": "company",
                "datetime": 1788185460,
                "headline": "Nomura Value Fund Q2 2026 Portfolio Activity"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141361112,
                "url": "https://finnhub.io/api/news?id=d8d9f29d23f8ccc5a8039fb4f8d576454a33559eca689894c965058ad1ebf9a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "August has been a great month for the shares of Merck & Co., Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA), to say the least. The former’s stock closed 12.6% higher and the latter’s stock closed 176% higher on August 19th. The stocks surged after a major announcement from Moderna Inc. (NASDAQ:MRNA) shared the results from its […]",
                "category": "company",
                "datetime": 1788158154,
                "headline": "Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck’s Trial Results Encouraging"
              },
              {
                "id": 141361119,
                "url": "https://finnhub.io/api/news?id=5567db3cbce531d3c4fd84a637eb2aacb230997017083d16e7448c6d05940a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "SCHD just delivered a return most dividend investors spend a decade waiting for, and that success created a problem nobody predicted. Whether fresh money belongs in the fund right now depends on a tradeoff that long-term holders never had to face.",
                "category": "company",
                "datetime": 1788132325,
                "headline": "SCHD Is Up Nearly 30% and Its Yield Is Back Near 3% | Did Dividend Investors Miss the Easy Money?"
              },
              {
                "id": 141361106,
                "url": "https://finnhub.io/api/news?id=330a0319a7e0635308b52b8c3af730970549573bdd7e850be38befb61f99a2d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck has surged past the broader Nasdaq Composite over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.",
                "category": "company",
                "datetime": 1788120934,
                "headline": "Is Merck Stock Outperforming the Nasdaq?"
              },
              {
                "id": 141361107,
                "url": "https://finnhub.io/api/news?id=604a74c67cc76ee833e91a11b652ccba9c35816d3796c281b4852b3f31915326",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK) and Moderna report the first positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients. The therapy was tested in combination with Merck's immunotherapy KEYTRUDA in a Phase 3 trial setting. This marks the first time an mRNA-based individualized neoantigen approach has shown clinically meaningful and statistically significant Phase 3 data in cancer. The result signals a potential new path for personalized cancer vaccines with...",
                "category": "company",
                "datetime": 1788095722,
                "headline": "Merck (MRK) Posts First Positive Phase 3 Result For Personalized mRNA Melanoma Therapy"
              },
              {
                "id": 141361108,
                "url": "https://finnhub.io/api/news?id=4283f23d94cd6939bf9492a401776c8818a3837d266c5cd9700d5961e27b7c07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June. The spark was a single piece of clinical trial news: Moderna Inc. (NASDAQ:MRNA) and Merck […]",
                "category": "company",
                "datetime": 1788087780,
                "headline": "Healthcare’s Best Week Since June Traces Back to a Single Moderna and Merck Cancer Trial"
              },
              {
                "id": 141361113,
                "url": "https://finnhub.io/api/news?id=66fec465e4c89bac40a78eb914eb8ac5d4d59922ab72ad142eae213f419a9b70",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "On the August 26 episode of Mad Money, a caller mentioned that they had purchased 1,000 shares of Moderna, Inc. (NASDAQ:MRNA) at $54 a couple of weeks prior, watched the price go up to $150, and asked what they should do. Jim Cramer replied: Here’s what I would do: I think that you have to […]",
                "category": "company",
                "datetime": 1787952295,
                "headline": "Jim Cramer Says Hold on to Moderna (MRNA) After Phase 3 Cancer Trial"
              },
              {
                "id": 141348569,
                "url": "https://finnhub.io/api/news?id=5caec48fa8c298b9b7ae22abf3e8a0748a26e4cee3ef928bc307c833666febd5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The signs were not in the headline growth rate but in which two products were trading places.",
                "category": "company",
                "datetime": 1787947785,
                "headline": "Did A Product Swap Fuel JNJ Stock’s 54% Surge?"
              },
              {
                "id": 141361121,
                "url": "https://finnhub.io/api/news?id=768a75ca19c35df540bbddc98ae5977f685be591565b6a60990acc1b1816a6b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BioNTech says it’s ending a Phase 2 trial for its investigational personalized mRNA cancer vaccine. It was being tested to treat colorectal cancer.",
                "category": "company",
                "datetime": 1787946240,
                "headline": "BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna’s Big Win"
              },
              {
                "id": 141348570,
                "url": "https://finnhub.io/api/news?id=4f0e161ba9b9cba902841c73156b0682cae4aa772893993f336979cf573e608d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Revenue grew at its usual pace over the past year while the stock outran its biggest peers, and the gap sits in a run of clinical readouts that landed early.",
                "category": "company",
                "datetime": 1787945738,
                "headline": "Can Merck Stock Outrun Its Pipeline?"
              },
              {
                "id": 141339387,
                "url": "https://finnhub.io/api/news?id=5b27de5152d79b81f60ff69ee0c2f519f474646bac52a822fe2fd7513d0b0db2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Get insights into the dow jones index performance on Friday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1787944206,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 141361124,
                "url": "https://finnhub.io/api/news?id=f706f1ea4a86a23d6768be3b0540c0f35678d639d8b0ceb699785025db0631a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BioNTech (BNTX) shares slumped Friday after the company said it is terminating a mid-stage clinical",
                "category": "company",
                "datetime": 1787942820,
                "headline": "BioNTech Terminates Phase 2 Colorectal Cancer Clinical Trial; Shares Fall"
              },
              {
                "id": 141361123,
                "url": "https://finnhub.io/api/news?id=a229776adfbd2f478759fe9524731e4ae216e3235018194f23142aea4be40078",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BioNTech said on Friday that it and its partner, Genentech, a Roche unit, are ending the mid-stage study of autogene cevumeran, used alone after surgery, in certain high-risk stage II or III colorectal cancer patients.",
                "category": "company",
                "datetime": 1787941321,
                "headline": "BNTX Stock On Track For Worst Day Since March After Cancer Vaccine Trial Halt — BMO Capital Terms It ‘Clear Setback’"
              },
              {
                "id": 141338491,
                "url": "https://finnhub.io/api/news?id=55cae651cbeff84fbf63cc5a69133b5bb10f6b6420ada6c314a3e1af3a9e0019",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787935206,
                "headline": "Stay informed with the top movers within the dow jones index on Friday."
              },
              {
                "id": 141338793,
                "url": "https://finnhub.io/api/news?id=bd81a66323ddaec8a6c063ad55e9bab105eb706d36589a0de58b89f58003aded",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report",
                "category": "company",
                "datetime": 1787921002,
                "headline": "World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency"
              },
              {
                "id": 141332704,
                "url": "https://finnhub.io/api/news?id=5433b90d434ccadf5fa25840410d7ff01912ef51cbc03381fbdc7a0328c91add",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.",
                "category": "company",
                "datetime": 1787864703,
                "headline": "What's going on in today's after hours session: S&P500 movers"
              },
              {
                "id": 141332703,
                "url": "https://finnhub.io/api/news?id=d854a50559f4c80953210ae0c5c722cc139602482c61ff4b2f8fc1ded4d1a701",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.",
                "category": "company",
                "datetime": 1787864400,
                "headline": "Stay updated with the stocks that are on the move in today's after-hours session."
              },
              {
                "id": 141332096,
                "url": "https://finnhub.io/api/news?id=f91bace257ba0af744e76346de1ee986e0b1ace6e3fd1e564f4da44e81506cdf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1787857806,
                "headline": "Thursday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 141331062,
                "url": "https://finnhub.io/api/news?id=5c23c716656d25f98d61da7895898b299ef98b2bd2a7cea04355a7c099030532",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1787848807,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 141331717,
                "url": "https://finnhub.io/api/news?id=b76b2b2c443ab9cdc5e0d7b1f80faa2c059934c65cbfad7ab85c3c4e47c4c2d8",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787837726,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 141331719,
                "url": "https://finnhub.io/api/news?id=997531e2ee255677892a76e5ee557d2bbc12a11a127519612b721cb6ab5be5c9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/27/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.",
                "category": "company",
                "datetime": 1787823061,
                "headline": "Moderna Borrows $2 Billion To Expand Oncology Business"
              },
              {
                "id": 141329551,
                "url": "https://finnhub.io/api/news?id=320a5de29203b8e44f2edf5548e3915f957e76feed78625c85f5fe1da7b57b64",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217679967/image_2217679967.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.",
                "category": "company",
                "datetime": 1787818087,
                "headline": "GSK: Still One Of My Top Healthcare Picks"
              },
              {
                "id": 141325070,
                "url": "https://finnhub.io/api/news?id=3417a3fd58c9acd17e69c9a0d87f708c3e8f3e97dd028fe9fbdbf7f909b2946c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241406516/image_2241406516.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Summit Therapeutics is upgraded to Buy as sentiment bottoms and ivonescimab catalysts near; assess upside vs. cash burn. Click for this SMMT update.",
                "category": "company",
                "datetime": 1787762627,
                "headline": "Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade)"
              },
              {
                "id": 141323760,
                "url": "https://finnhub.io/api/news?id=41d4f97dcb9c14125228f555e756c21cedb80f2461e657928ccf4a89931d142e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Wednesday.",
                "category": "company",
                "datetime": 1787762405,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 141323666,
                "url": "https://finnhub.io/api/news?id=639a09fd66eb61566ebe38db1bdd8d933cab4a796973b124b878d52985839f21",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/26/Lung-research.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.",
                "category": "company",
                "datetime": 1787733069,
                "headline": "EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer"
              },
              {
                "id": 141322441,
                "url": "https://finnhub.io/api/news?id=ea4ad1157b42d6bad453f53df9599e9e64e5dddcb48416e8ed75336323562ec6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177662436/image_2177662436.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "STK yields 3.56% with special distribution potential, while SCHD's 2.98% yield reflects strong price appreciation. Check out the strategy with SCHD and STK here.",
                "category": "company",
                "datetime": 1787731200,
                "headline": "SCHD And STK: A 3%+ Income Barbell"
              },
              {
                "id": 141323952,
                "url": "https://finnhub.io/api/news?id=47f0f4739447dbe1e4ab1b7802e30af37c28a05f9004cf1fef4b9032da320780",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/26/Washington--March-4-2025-House-Speaker-M.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Johnson credits Trump and Republicans for record low drug prices, stating Americans are seeing lower costs and more money in their pockets.",
                "category": "company",
                "datetime": 1787716600,
                "headline": "Mike Johnson Says Prescription Drug Prices Are at 'Lowest Levels' in 60 Years, Credits Trump and Republicans for Lower Costs"
              },
              {
                "id": 141317034,
                "url": "https://finnhub.io/api/news?id=a8858e98310f85462059e252bd76fc3444519de43c88f68833ab57142ce4739b",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787676006,
                "headline": "Top dow jones movers in Tuesday's session"
              },
              {
                "id": 141323880,
                "url": "https://finnhub.io/api/news?id=5e113f1e4a5c7ac536bb10cef8d1cc08f3629e7b2a6fdb156dede6adc97e627f",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/Measles-Cases-Rising-In-The-U-S.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Two unvaccinated Pennsylvania residents died of measles, the state’s first deaths in 35 years, as traders see 89% odds of 4,000 U.S. cases.",
                "category": "company",
                "datetime": 1787671868,
                "headline": "Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?"
              },
              {
                "id": 141323954,
                "url": "https://finnhub.io/api/news?id=feaa40a37abd68c3c741e376a9ce763a101b102aa51ed1c41a8739f48f6db204",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Wolfe Research  analyst Alexandria Hammond   maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $155 to $180.",
                "category": "company",
                "datetime": 1787657254,
                "headline": "Wolfe Research Maintains Outperform on Merck & Co, Raises Price Target to $180"
              },
              {
                "id": 141316572,
                "url": "https://finnhub.io/api/news?id=7fe7b223afcf23593d669003942bf277a43bdfd0531baf348b2491a66804c553",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Shares of Moderna are trading higher Tuesday morning, as Wall Street analysts upgrade their ratings following landmark Phase 3 oncology data.",
                "category": "company",
                "datetime": 1787649528,
                "headline": "Moderna Stock Edges Higher Tuesday: What's Happening?"
              },
              {
                "id": 141316212,
                "url": "https://finnhub.io/api/news?id=5e6fefaa99fcd424019f11ce4f04ca63d98863c1cd874b1f5971c0ae40aed934",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2230550003/image_2230550003.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Regeneron Pharmaceuticals, Inc. stock outlook: Eylea pressure eases as Dupixent jumps; FDA OKs Pasatru. Read why REGN stock is a buy.",
                "category": "company",
                "datetime": 1787648487,
                "headline": "Regeneron: Why I Still See Upside After The Rally"
              },
              {
                "id": 141316573,
                "url": "https://finnhub.io/api/news?id=a9e2d0495dc8bffed6d50886632b6bb63b929830c48bf1780601c22a0f3dfc61",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Argus Research  analyst Jasper Hellweg   maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $145 to $170.",
                "category": "company",
                "datetime": 1787648282,
                "headline": "Argus Research Maintains Buy on Merck & Co, Raises Price Target to $170"
              },
              {
                "id": 141316574,
                "url": "https://finnhub.io/api/news?id=e8f97845fa9279e067be7735bdf71aa836c12f20defc88a9f30ecd41bd4021df",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/Merck.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Court rejects Merck's lawsuit against Medicare drug price negotiations. Penalties for noncompliance include steep excise taxes.",
                "category": "company",
                "datetime": 1787647977,
                "headline": "Court Rejects Merck’s Challenge to Medicare Drug Price Negotiation Program"
              },
              {
                "id": 141310307,
                "url": "https://finnhub.io/api/news?id=48b8fa88bd71ad9473b96e5509ddc70b6ba7cf91f9ae99697aa25dfc525580c6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/24/Tempus-AI.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.",
                "category": "company",
                "datetime": 1787580171,
                "headline": "What’s Going On With Tempus AI Stock on Monday?"
              },
              {
                "id": 141308999,
                "url": "https://finnhub.io/api/news?id=83e48b2f15c8beaaf87c51ef86b2c38318b4baa7c46a7bac56ad7e9db1c063cd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/24/Oz-Touts-One-More-Working-Year.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “quite lethal” amid vaccine policy scrutiny.",
                "category": "company",
                "datetime": 1787534390,
                "headline": "Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine Policy"
              },
              {
                "id": 141302707,
                "url": "https://finnhub.io/api/news?id=351dfe7f68e2c28e4d40783769fb6f7a700d7362c99c21188d8c8b276c972f91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Tempus AI's latest acquisition is looking like a great move.",
                "category": "company",
                "datetime": 1787488500,
                "headline": "Why Tempus AI Skyrocketed This Week"
              },
              {
                "id": 141302633,
                "url": "https://finnhub.io/api/news?id=710f3c3ca6e342bdec112e491629522821f6eb5c5c8bf1a9882b2cb278aa4676",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.",
                "category": "company",
                "datetime": 1787415000,
                "headline": "2 Biotech Stocks Shaping Up for Major Breakouts"
              },
              {
                "id": 141302612,
                "url": "https://finnhub.io/api/news?id=76547bac59c31a668d5e46df733d737aea57e6553f790608f61b8ad98abfced1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Stocks fell this week as Treasury bond buybacks, oil prices, and Walmart earnings weighed on markets, while Bitcoin rallied; MarketBeat analysts cover Moderna, NVIDIA, Meta, RTX, and more.",
                "category": "company",
                "datetime": 1787400000,
                "headline": "MarketBeat Week in Review – 08/17 - 08/21"
              },
              {
                "id": 141278399,
                "url": "https://finnhub.io/api/news?id=82086bc1efdaa2e00d5b62aee111cce8180f32a2ecd47272d983de05a06c52ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Check out the companies making headlines this week:",
                "category": "company",
                "datetime": 1787388819,
                "headline": "Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical"
              },
              {
                "id": 141294364,
                "url": "https://finnhub.io/api/news?id=9c7c4b6e7a4bd983931392cae935ba5ee7de9fcf2e7462339dc649abae2c0a2a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/22/Bulls-and-Bears-1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.",
                "category": "company",
                "datetime": 1787385673,
                "headline": "Benzinga Bulls and Bears: Ross, Moderna, Webull"
              },
              {
                "id": 141278394,
                "url": "https://finnhub.io/api/news?id=682b10a24c0fe3439d30e49918a13068df09a090fa5d18e903888984f117b0a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.",
                "category": "company",
                "datetime": 1787361546,
                "headline": "ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’"
              },
              {
                "id": 141278219,
                "url": "https://finnhub.io/api/news?id=350fe7c8ba98e6524dd17860ad5c469797b726189c22f238eecd4e743634c106",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna's 130% day ran on five conditions. We screened the market for stocks like Moderna and found three names, none a biotech.",
                "category": "company",
                "datetime": 1787354045,
                "headline": "3 American Stocks Showing the Same Setup That Sent Moderna Up 177%"
              },
              {
                "id": 141278395,
                "url": "https://finnhub.io/api/news?id=b65b0ac5786dd2b0dce71b5e3f2603194a23e2f203ea0237c5a61f9d1c7c1541",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes \"Moderna and Merck's Cancer Vaccine Is a Marvel.\"",
                "category": "company",
                "datetime": 1787353141,
                "headline": "Moderna, Merck Cancer Vax Gives Hope"
              },
              {
                "id": 141278401,
                "url": "https://finnhub.io/api/news?id=c0c318a6613f04793c35da84472cfac03ee0702d00d8d6e7de919298c14b9dbd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The stock has gained over 20% in the past five days, marking its best week since early July.",
                "category": "company",
                "datetime": 1787350771,
                "headline": "SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation"
              },
              {
                "id": 141273220,
                "url": "https://finnhub.io/api/news?id=8140b108801b2d518124ff23a413996f21d5e457e117de7876aca0b97880d25a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna shares rise to close out a week of wild swings. Crypto stocks also extend their recent rally.",
                "category": "company",
                "datetime": 1787347080,
                "headline": "Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141278392,
                "url": "https://finnhub.io/api/news?id=14b714ba3624eef820e06616a6950f7615f094ca1181f80b5a06906127e469eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck (MRK) is back in focus after announcing that its personalized mRNA cancer vaccine, intismeran autogene, combined with Keytruda, achieved statistically significant gains in keeping high-risk melanoma from recurring or spreading in a Phase 3 trial. See our latest analysis for Merck. Merck’s recent mRNA melanoma result has arrived alongside powerful price momentum, with a 30 day share price return of 18.0% and a year to date share price return of 40.0%. The 1 year total shareholder return...",
                "category": "company",
                "datetime": 1787343021,
                "headline": "Merck (MRK) Gains A New Cancer Growth Story As Valuation Debate Heats Up"
              },
              {
                "id": 141278402,
                "url": "https://finnhub.io/api/news?id=c007d7ae352542bcd167be2873b9aa69ef81d0951a36bac9af3d7ff47e073bfd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "It's been a good week for healthcare, with one stock's dramatic gains driving the sector higher.  Moderna stock saw its best weekly performance ever, rising over 140%.  The stock surged after the pharmaceutical giant announced promising results out of trials for its cancer vaccine.",
                "category": "company",
                "datetime": 1787342256,
                "headline": "Thank Moderna for the Healthcare Sector’s Standout Week"
              },
              {
                "id": 141278397,
                "url": "https://finnhub.io/api/news?id=38dd0d7e7c6eb6285ae70cc42b7302f86dda418041d32af3c76017a0115b343f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers",
                "category": "company",
                "datetime": 1787342040,
                "headline": "Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players"
              },
              {
                "id": 141278028,
                "url": "https://finnhub.io/api/news?id=b85cf2c4c1752d6b68a87ce0e31deed248fb731b2165e96279cc313ac08ca183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.",
                "category": "company",
                "datetime": 1787341256,
                "headline": "Lilly's Multiple Assumes Less Growth Than You Think"
              },
              {
                "id": 141278404,
                "url": "https://finnhub.io/api/news?id=788d907d139c172024a8da133d9395afb9596075f23fe3075ee239879373a942",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Investing.com -- A historic single-day move in biotech dominated the week, while a Treasury liquidity announcement impacted crypto and metals. Two well-known consumer names went in opposite directions on earnings.",
                "category": "company",
                "datetime": 1787340370,
                "headline": "Investing.com’s stocks of the week"
              },
              {
                "id": 141278398,
                "url": "https://finnhub.io/api/news?id=627be7edc9f9bb24e26e8db1d3eb01a347be9c47be9302779448c5d5f59825cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you still buy the dip?",
                "category": "company",
                "datetime": 1787340255,
                "headline": "Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet."
              },
              {
                "id": 141272166,
                "url": "https://finnhub.io/api/news?id=2a96d4aa691194c3fc85b2b1ae496aa054a0278a839aae1dbc4db975bd1f5df7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Friday.",
                "category": "company",
                "datetime": 1787339405,
                "headline": "Discover which dow jones stocks are making waves on Friday."
              },
              {
                "id": 141278037,
                "url": "https://finnhub.io/api/news?id=2171816a642cf2107b69f459ff8b534241a7636c5e34d5621c3285981f97c7b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.",
                "category": "company",
                "datetime": 1787338129,
                "headline": "Most Of What Moves AbbVie Stock Has Nothing To Do With The Market"
              },
              {
                "id": 141273836,
                "url": "https://finnhub.io/api/news?id=54587dab906d987614824cfab5a6a06e39d1174079f537b68a0616ac939e493d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Retail investors talked up 5 hot stocks during the week (Aug. 17 to Aug. 21) on X and Reddit's r/WallStreetBets: MRNA, WMT, MSTR, AVGO, SPCX",
                "category": "company",
                "datetime": 1787335233,
                "headline": "MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week"
              },
              {
                "id": 141277968,
                "url": "https://finnhub.io/api/news?id=1e4615f8e1b0d39cf4bb95c8d366f753b589b376f16cb64b0bc07124df58698f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "JEPI's 8% monthly yield looks like an obvious win over SCHD's modest payout, but the IRS treats those two income streams in ways that can quietly flip the comparison depending on where you hold them.",
                "category": "company",
                "datetime": 1787333431,
                "headline": "The Hidden Tax Cost of JEPI’s Monthly Income Machine"
              },
              {
                "id": 141278407,
                "url": "https://finnhub.io/api/news?id=d2ae63aea5848dbdb0dc5c06d23db65d6bf8f8dc67b166696e8cd91b37bc9c48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.",
                "category": "company",
                "datetime": 1787328060,
                "headline": "Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?"
              },
              {
                "id": 141278393,
                "url": "https://finnhub.io/api/news?id=e6d1600ee7d1ec88e3dc6b767a5510c4cf0f8a286e4e646f96fb5a20f761e9ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck's (MRK) near-term catalysts remain attractive, but execution risks are underestimated at its c",
                "category": "company",
                "datetime": 1787327862,
                "headline": "Merck's Near-Term Catalysts Create Bull-Bear Debate, RBC Capital Markets Says"
              },
              {
                "id": 141278408,
                "url": "https://finnhub.io/api/news?id=2ddaa36f268f9adaf00de0f198d3373105e8c7d625ebfb78af1ff712f151bdcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.",
                "category": "company",
                "datetime": 1787327520,
                "headline": "JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know"
              },
              {
                "id": 141278409,
                "url": "https://finnhub.io/api/news?id=0693331366acda03bfcd5a167bea14df1950cd4e7abffeb35a05ea64ba6e2429",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "The market rally flashed some bearish signals. Moderna skyrocketed on a cancer vaccine while gold and bitcoin jumped. Walmart dived.",
                "category": "company",
                "datetime": 1787326311,
                "headline": "Stock Market Rally Buckles; Moderna, Gold, Bitcoin Surge While Walmart Tumbles: Weekly Review"
              },
              {
                "id": 141278410,
                "url": "https://finnhub.io/api/news?id=11965b7623d404e18587fc0c0bbc876ea040961b86425f3109227d7743d0a687",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.",
                "category": "company",
                "datetime": 1787324767,
                "headline": "Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session"
              },
              {
                "id": 141295964,
                "url": "https://finnhub.io/api/news?id=0aec6ff5d6453cc7db3e139989c608f4ea219aa262d28627225ce63fef3cdd58",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Goldman Sachs  analyst Terence Flynn   maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $140 to $160.",
                "category": "company",
                "datetime": 1787320262,
                "headline": "Goldman Sachs Maintains Buy on Merck & Co, Raises Price Target to $160"
              },
              {
                "id": 141273478,
                "url": "https://finnhub.io/api/news?id=efefe9bbbeab1654bc7f7bef800af2a084503a6408f913658e7b1ab0e71a833a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Moderna-Logo-With-Vials-And-Syringe.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna stock soars on recent Phase 3 trial results. A look back at the company's IPO and the stock's ups and downs since.",
                "category": "company",
                "datetime": 1787317764,
                "headline": "If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now"
              },
              {
                "id": 141270540,
                "url": "https://finnhub.io/api/news?id=116c11c87c38da79036c16efcd11562a853d9083eec117f66078dbf626d0cc71",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2229006239/image_2229006239.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "SCHD beat bearish macro trends as ABT, MRK & AMGN surged. Learn why dividend growth makes waiting costly—and what to do now.",
                "category": "company",
                "datetime": 1787311688,
                "headline": "SCHD: We Were Horribly Wrong"
              },
              {
                "id": 141274441,
                "url": "https://finnhub.io/api/news?id=75bb137aea44f47bfd17ffe54415ef6589f9d8609752bb4b94002ea857dfd2b0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Kyiv--Ukraine---December-01--2020-Modern.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna's Phase 3 cancer vaccine breakthrough could mark a turning point as the biotech company looks to move beyond its COVID-era identity.",
                "category": "company",
                "datetime": 1787309089,
                "headline": "COVID-19 Made Moderna Famous: Cancer Could Define Its Future"
              },
              {
                "id": 141268893,
                "url": "https://finnhub.io/api/news?id=6ce35ac37bb20f3f0877546c5a59b6279b06bd0bba9d04f6c33f383c18cea0c3",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_2026_08_21T105840_288_f7f25158ae.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "US stocks closed sharply lower on Thursday, August 20, 2026, as Walmart's downbeat outlook wiped nearly 10% off the shares, President Trump threatened Iran with the harshest sanctions package ever from Monday, and long-dated Treasury yields ticked higher again. John Deere's Q3 beat and a bitcoin surge past $70,000 offered the only real bright spots.",
                "category": "company",
                "datetime": 1787301595,
                "headline": "Walmart's Guide-Down Sinks the Dow as Trump Readies an \"Economic D-Day\" for Iran"
              },
              {
                "id": 141264942,
                "url": "https://finnhub.io/api/news?id=6b2d6f629029cf11b512a21dd621d62f68ddf0541aa63dca6bc1af665f17b726",
                "image": "",
                "source": "Fintel",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1787260964,
                "headline": "Morgan Stanley Upgrades Merck (MRK)"
              },
              {
                "id": 141264943,
                "url": "https://finnhub.io/api/news?id=1e3dafc16f1aa0852ee7b8052e8d6cbde64464cd12a240c1346087f5fd870881",
                "image": "",
                "source": "Fintel",
                "related": "MRK",
                "summary": "",
                "category": "company",
                "datetime": 1787260927,
                "headline": "RBC Capital Downgrades Merck (MRK)"
              },
              {
                "id": 141263370,
                "url": "https://finnhub.io/api/news?id=25d499e46aeb182c99566a316b221ca050055e16c61d83cc8d1dd14cfb670a63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Buy XBI now: SPDR S&P Biotech ETF up 34% since March on M&A and trial catalysts.",
                "category": "company",
                "datetime": 1787235957,
                "headline": "XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)"
              },
              {
                "id": 141264444,
                "url": "https://finnhub.io/api/news?id=2aadb4debe16219f9578212ef6073d8a48dd765776e660a254ec7af57c751400",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Benzinga-Quick-Spark.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna closed up 176.97% on first-ever Phase 3 win for an mRNA cancer vaccine, then gave back as much as a quarter of it the next day.",
                "category": "company",
                "datetime": 1787233734,
                "headline": "QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History"
              },
              {
                "id": 141264445,
                "url": "https://finnhub.io/api/news?id=26c66c90693f113fcdcb8e31a0145db813cec940e40601108c5ec80d9f483aea",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "BMO Capital  analyst Evan David Seigerman   maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $142 to $170.",
                "category": "company",
                "datetime": 1787231852,
                "headline": "BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to $170"
              },
              {
                "id": 141263663,
                "url": "https://finnhub.io/api/news?id=b9ae4613669603267f6c067feff6ec8de6891cf3e48fff5457fb7f1907a8f1c0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/3D-Illustration-Depicting-Cancer-Cells-I.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.",
                "category": "company",
                "datetime": 1787231698,
                "headline": "Why Iovance Biotherapeutics Stock Hit 52-Week High"
              },
              {
                "id": 141262459,
                "url": "https://finnhub.io/api/news?id=9021eeb7a35491dc80db4c2e3fd5961bac28c1ea35a80349dd6d11d3752f9431",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Operations-Research-Analysts.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Wall Street analysts changed outlook on top names. Check all rating changes, including upgrades/downgrades, on Benzinga analyst ratings page.",
                "category": "company",
                "datetime": 1787227285,
                "headline": "This Allstate Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday"
              },
              {
                "id": 141264449,
                "url": "https://finnhub.io/api/news?id=b486314f5901a23c345bd00dd1f4a8b8b7cf8db7be0656480fff2c086171ee55",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "UBS  analyst Michael Yee   maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $145 to $175.",
                "category": "company",
                "datetime": 1787226804,
                "headline": "UBS Maintains Buy on Merck & Co, Raises Price Target to $175"
              },
              {
                "id": 141264450,
                "url": "https://finnhub.io/api/news?id=81953aae4b3cce9c57f1f27ba6c6ee7d0fe9fd5f5db41ca84814fbaf25814bd8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "William Blair upgraded Moderna to Outperform, citing higher intismeran approval odds and a multibillion-dollar oncology sales opportunity.",
                "category": "company",
                "datetime": 1787223773,
                "headline": "Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst"
              },
              {
                "id": 141264451,
                "url": "https://finnhub.io/api/news?id=e364d34edd74c3a91ce7f75c7ee70df5c7736a2fa21697300eb64ccd2f2bc953",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "RBC Capital  analyst Trung Huynh   downgrades Merck & Co (NYSE:MRK) from Outperform to Sector Perform and raises the price target from $142 to $150.",
                "category": "company",
                "datetime": 1787218185,
                "headline": "RBC Capital Downgrades Merck & Co to Sector Perform, Raises Price Target to $150"
              },
              {
                "id": 141264452,
                "url": "https://finnhub.io/api/news?id=8799c7b1be844f7bdd70b8d12c7c28fc8dcbbf1604870732897f7c765a3b0b8b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Gut-Microbiome-Linked-Colon-Cancer.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Pharma Bro Martin Shkreli admits shorting Moderna at $80 just weeks before a landmark cancer vaccine win sparked a 177% stock explosion.",
                "category": "company",
                "datetime": 1787215976,
                "headline": "Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’"
              },
              {
                "id": 141261708,
                "url": "https://finnhub.io/api/news?id=df7fb2326ca435c2e0f77e8e0e2822a914fc0718cf97c8bc8a9cbcdde6ae8fe1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Merck-Logo--Sign-At-Merck-Research-Labor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Wall Street analysts upgraded PGR, MRK, EPR and initiated coverage on BEKE and IONS. Check analyst ratings and price targets for these stocks.",
                "category": "company",
                "datetime": 1787215845,
                "headline": "This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday"
              },
              {
                "id": 141261780,
                "url": "https://finnhub.io/api/news?id=bdf52e47b57a45524ab51963ebe64f43e347599af34cade8a165280971f79d8d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Editor’s note: The ETFs data was updated and economic data was added\n\n\n\nU.S. stock futures were lower on Thursday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Wednesday’s higher",
                "category": "company",
                "datetime": 1787214974,
                "headline": "Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Fall as Trump Launches ‘Operation Economic Fury’ on Iran— BULL, WMT, MRK Stock in Focus (UPDATED)"
              },
              {
                "id": 141264455,
                "url": "https://finnhub.io/api/news?id=a927e529fa3d828492e6c559d766861b09c7978686f9c68f42c09ae836f8fede",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Tempus-AI.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Tempus AI (TEM) trades higher after positive Phase 3 mRNA cancer trial results spotlight its $1.5B acquisition of Personalis.",
                "category": "company",
                "datetime": 1787214954,
                "headline": "Why Is Tempus AI Stock Gaining Thursday?"
              },
              {
                "id": 141261710,
                "url": "https://finnhub.io/api/news?id=6eabbfd293f00b11fa7b0d65344a4f503d89c94b82d3fbd4985dd1bdd77570cb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Okta-Sign-Building-In-Soma-District--Okt.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.",
                "category": "company",
                "datetime": 1787213997,
                "headline": "Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday"
              },
              {
                "id": 141264457,
                "url": "https://finnhub.io/api/news?id=0f35252255458197d640a9a6e84e4d446dab53e84ac4b4f95fe5bd54531381f7",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Paris--France---June-16--2023-Elon-Musk-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.",
                "category": "company",
                "datetime": 1787213910,
                "headline": "Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)"
              },
              {
                "id": 141261028,
                "url": "https://finnhub.io/api/news?id=5b54ec56dfde684c05d3723c87da63c116166a04b8bff3d3ea948663950358c1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2280454849/image_2280454849.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.",
                "category": "company",
                "datetime": 1787212800,
                "headline": "Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance"
              },
              {
                "id": 141260840,
                "url": "https://finnhub.io/api/news?id=165a75973e927f5ee7ac0860bb27345b6c37d6d881bd329434f668c0f8cd6f45",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150626840/image_2150626840.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Moderna and Merck have been running a large Phase III trial in over a thousand high-risk patients who had already had surgery to remove cutaneous melanoma tumors. Read more here...",
                "category": "company",
                "datetime": 1787210100,
                "headline": "Merck And Moderna's Melanoma Results"
              },
              {
                "id": 141260096,
                "url": "https://finnhub.io/api/news?id=508d178665ed408c01403249081d5127f914ba13062aa866c375984e312e5d86",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_2026_08_20T091541_987_28e8b314a3.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "US stocks eked out a modest gain on Wednesday, August 19, 2026, as Moderna nearly tripled on a landmark cancer vaccine readout, Marvell locked in a multi-billion Google chip deal, and Treasury doubled its long-bond buyback program. Fed minutes leaned more hawkish than expected.",
                "category": "company",
                "datetime": 1787209874,
                "headline": "Moderna Doubles on Melanoma Vaccine Win, Treasury Steps In to Cap Long-End Yields"
              },
              {
                "id": 141264458,
                "url": "https://finnhub.io/api/news?id=ba5dd1d185490c702b88faf64ac5315c092304d3ea1a5d57753db3e5344814d7",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Morgan Stanley  analyst Terence Flynn   upgrades Merck & Co (NYSE:MRK) from Equal-Weight to Overweight and raises the price target from $116 to $179.",
                "category": "company",
                "datetime": 1787206027,
                "headline": "Morgan Stanley Upgrades Merck & Co to Overweight, Raises Price Target to $179"
              },
              {
                "id": 141261726,
                "url": "https://finnhub.io/api/news?id=1df584cc6d7462b6d1e0b4f407b260328535dd377744c94401139924e9f92628",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Financial-Market-Bubble-Concept-And-Over.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.",
                "category": "company",
                "datetime": 1787205550,
                "headline": "Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why"
              },
              {
                "id": 141262665,
                "url": "https://finnhub.io/api/news?id=b0b45e0aa2252c3139c04f29290c2ff67281f3d367193842f501696a5d7d533d",
                "image": "https://image.cnbcfm.com/api/v1/image/108347527-1786391307504-gettyimages-2277156932-WARSH_SWEAR_IN.jpeg?v=1786391350&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "President Donald Trump is raging against rates, vowing economic warfare on Iran and lending support to crypto regulation in a busy environment for investors.",
                "category": "company",
                "datetime": 1787192542,
                "headline": "CNBC Daily Open: Trump bemoans 'ridiculous rates'"
              },
              {
                "id": 141261727,
                "url": "https://finnhub.io/api/news?id=593eab7b6696fb79c76c1ab87310ffe191bf52224478eb4fdd74003a3801cac6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Two-Vials-Of-The-Moderna-Vaccine-With-A-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.",
                "category": "company",
                "datetime": 1787182165,
                "headline": "Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight"
              },
              {
                "id": 141262788,
                "url": "https://finnhub.io/api/news?id=623e3eca786973c739559db7e1fc03a28af1d6ca7ffa38063895e0af2ab9be22",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Displaying-Scrolling-Stock-Tickers-And-C.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Major U.S. indices closed higher on Wednesday, with the Dow Jones Industrial Average rising 0.22% to 53,463.05.",
                "category": "company",
                "datetime": 1787175285,
                "headline": "Moderna, Webull, Bitmine Immersion, Strategy and Merck: Why These 5 Stocks Are on Investors' Radars Today"
              },
              {
                "id": 141262666,
                "url": "https://finnhub.io/api/news?id=cc88f161424452008ad368e9f90f6cd385bdc432524e1179d0c4219cb7a6795f",
                "image": "https://image.cnbcfm.com/api/v1/image/108351875-1787178100146-gettyimages-2290607138-AFP_C62Z247.jpeg?v=1787178332&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "On Wednesday, the Treasury Department's decision to double its purchases of longer-dated bonds sent yields lower and gave stocks some breathing room.",
                "category": "company",
                "datetime": 1787175088,
                "headline": "CNBC Daily Open: Treasury attempts to rein in bond yields as U.S. debt swells past $40 trillion"
              },
              {
                "id": 141255654,
                "url": "https://finnhub.io/api/news?id=40115c3c3464e83a2660ead2dc4dec4295ca940e8503f339c0e49581f3b5cef4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Wednesday.",
                "category": "company",
                "datetime": 1787166605,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 141255653,
                "url": "https://finnhub.io/api/news?id=e46427aae39604591751787a13c6e26e654e9b8fcdfef2fc617183f68f47e48f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1787166301,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 141262667,
                "url": "https://finnhub.io/api/news?id=2643f39d47ae10903f710f0ae88830c6b8673d1b1f0ef7651e6e5a3bd0d5993e",
                "image": "https://image.cnbcfm.com/api/v1/image/108351867-17871760881787176084-47868097620-1080pnbcnews.jpg?v=1787176087&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk Merck and Moderna's stock moves on new cancer data.",
                "category": "company",
                "datetime": 1787161915,
                "headline": "Mizuho's Jared Holz on Moderna's leg up on new cancer shot data"
              },
              {
                "id": 141257271,
                "url": "https://finnhub.io/api/news?id=e659e73d22839029cea2173919dcf3b7ff288bcb4eeaab2bc415bc01a742d05d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Two-irregular-red-cells.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.",
                "category": "company",
                "datetime": 1787161748,
                "headline": "Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For"
              },
              {
                "id": 141262668,
                "url": "https://finnhub.io/api/news?id=5e728bc0b4fb4997d053d54879c5401e3b48ce55ceb4ace7a9d20f79018c0c5f",
                "image": "https://image.cnbcfm.com/api/v1/image/108351855-17871738141787173761-47867557643-1080pnbcnews.jpg?v=1787173813&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Courtney Breen, Bernstein, joins 'Closing Bell Overtime' to talk Merck and Moderna stocks rallying on news of cancer drug trial.",
                "category": "company",
                "datetime": 1787160044,
                "headline": "Bernstein's Courtney Breen talks the massive rally in Moderna stock"
              },
              {
                "id": 141254498,
                "url": "https://finnhub.io/api/news?id=a14e9232a459dfb79110228cde8185ff998722229b244931ed0f700428b0617d",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.",
                "category": "company",
                "datetime": 1787159100,
                "headline": "Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session."
              },
              {
                "id": 141254409,
                "url": "https://finnhub.io/api/news?id=9d113a09f48670d436e6f2252bf1887b5a026dfadda5e1b78c4e9f01efe715bf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787157301,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 141264463,
                "url": "https://finnhub.io/api/news?id=7bbf84c238e3a13000db20b9a045f91156c545d34a7eb025c6ef8670f5d06ace",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Moderna-Sign-With-Bold-Red-3D-Lettering-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Shareholders of Moderna stock saw big gains on Wednesday. The stock is part of President Donald Trump's portfolio.",
                "category": "company",
                "datetime": 1787156014,
                "headline": "Trump Adds to Wealth With Moderna Stock Gains: Here’s How Much President Made"
              },
              {
                "id": 141253496,
                "url": "https://finnhub.io/api/news?id=865016aa954b32bc2aa1313ff88956f0cf017e3f938aece960261cd4ce456bf8",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.",
                "category": "company",
                "datetime": 1787150102,
                "headline": "Which S&P500 stocks are gapping on Wednesday?"
              },
              {
                "id": 141255461,
                "url": "https://finnhub.io/api/news?id=8a923a2aeedb4a03f6cfb97eb0cbbceddf7628f540dbe08c20e1ddf7577c5e35",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Shanghai--China--Nov--6--2022-Pfizer-Sig.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck's deeper push into personalized cancer vaccines raises the competitive bar for Pfizer, BioNTech in biotech's fastest-growing race.",
                "category": "company",
                "datetime": 1787149875,
                "headline": "Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions"
              },
              {
                "id": 141255462,
                "url": "https://finnhub.io/api/news?id=2b286492921519f765948c500cb6a5dbb1095b7ae86a0c930813419698ce748e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Logo-Pfizer-Inc--Is-An-American-Multinat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that their combination therapy of intismeran autogene and Keytruda showed positive recurrence-free survival results in melanoma patients.",
                "category": "company",
                "datetime": 1787147774,
                "headline": "Pfizer Stock Rises Wednesday: What's Going On?"
              },
              {
                "id": 141254760,
                "url": "https://finnhub.io/api/news?id=57e8f02c2967b0da83b1675ff236e9b421b988cb254b927caefd66a83d832158",
                "image": "https://image.cnbcfm.com/api/v1/image/108351716-17871603111787160309-47864338582-1080pnbcnews.jpg?v=1787160310&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC's Annika Kim Constantino reports on the increase in Moderna and Merck's share prices following the success of late stage trials of cancer vaccines.",
                "category": "company",
                "datetime": 1787146069,
                "headline": "Moderna and Merck shares surge"
              },
              {
                "id": 141254702,
                "url": "https://finnhub.io/api/news?id=85516d8c008355770031d63deb6a804ab3ae2903871b25ce3955544dea3beff6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Global-Stock-Market-Rally-And-Bullish-Pe.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, aa gold soars.",
                "category": "company",
                "datetime": 1787145027,
                "headline": "Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today"
              },
              {
                "id": 141254712,
                "url": "https://finnhub.io/api/news?id=85690539df1f074b0141508ef60dd8720ee3792d4601920da3731c6695610e5e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "\n\n\n\nPlease click here for an enlarged chart of Moderna Inc (NASDAQ:MRNA).\n\n\n\nNote the following:\n\n\n\n\nThis article is about the big picture, not an individual stock.  The chart of MRNA stock is being used to illustrate",
                "category": "company",
                "datetime": 1787144995,
                "headline": "Investors Should Position For Humanoid Robot Boom—Here's A Picks-And-Shovels Play; First mRNA Cancer Vaccine Succeeds"
              },
              {
                "id": 141255466,
                "url": "https://finnhub.io/api/news?id=5a1e4b571ebfb2c67874e94c76a1594ee33097d7e1832173b68ce1b99dc89ea0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Biontech.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "BioNTech stock rises as Merck and Moderna report positive cancer vaccine data, highlighting its individualized mRNA cancer therapies.",
                "category": "company",
                "datetime": 1787143156,
                "headline": "Why Is BioNTech Stock Surging on Wednesday?"
              },
              {
                "id": 141253173,
                "url": "https://finnhub.io/api/news?id=c58a9c33229815012952c86e761766a0666280beddf95bea50271904dede2ca4",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session.",
                "category": "company",
                "datetime": 1787142901,
                "headline": "Top S&P500 movers in Wednesday's pre-market session"
              },
              {
                "id": 141254113,
                "url": "https://finnhub.io/api/news?id=332a7e0719712ea75c9aa97201b73d49a69acc28bde48ac76686737f51f41954",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. hits all-time highs on positive Phase 3 melanoma vaccine data with Moderna. Click for this MRK update.",
                "category": "company",
                "datetime": 1787141995,
                "headline": "Merck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead"
              },
              {
                "id": 141254575,
                "url": "https://finnhub.io/api/news?id=9d7e9e7f859431ad4d509702fbb12e5043156a5da79a8c786fba99c1fedadb5f",
                "image": "https://image.cnbcfm.com/api/v1/image/108351657-17871557251787155722-47863276120-1080pnbcnews.jpg?v=1787155724&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Simon Baker, Rothschild & Co Redburn global biopharma research co-head, joins 'Squawk on the Street' to discuss Moderna and Merck shares surging after an experimental personalized cancer vaccine from both companies showed positive initial results in its first-ever late-stage trial.",
                "category": "company",
                "datetime": 1787141969,
                "headline": "Moderna, Merck cancer vaccine data 'a great result, but not entirely unexpected', says Simon Baker"
              },
              {
                "id": 141254046,
                "url": "https://finnhub.io/api/news?id=e0c310d135d9f52c015bce90d67f1cfcf65240fd61b70cb6898f48f7303a4fce",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Merck & Co., Inc. stock: After a 72% surge, valuation and FY2027 earnings expectations cap upside. Click for this MRK update.",
                "category": "company",
                "datetime": 1787141290,
                "headline": "Merck: Why Consolidation Looks Like The Next Move (Rating Downgrade)"
              },
              {
                "id": 141255468,
                "url": "https://finnhub.io/api/news?id=81075d72f0e1257e25c20e6c8887ff8193b9c2985bc25e6ce0491257afbe647b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Biochemistry--Scientist-Working-In-Labor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna and Merck announce success of personalized cancer therapy trial. MRNA stock surges, but MRK may be more important for investors.",
                "category": "company",
                "datetime": 1787137936,
                "headline": "Moderna's Cancer Vaccine Win Is Merck's Story Too"
              },
              {
                "id": 141255469,
                "url": "https://finnhub.io/api/news?id=20b77426df96ac5e8ca9049a7559277387b7db199336f0bc9ea5baf067e90b6e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Moderna surged 151% on Phase 3 melanoma data with Merck, its biggest daily gain ever. Every Wall Street price target now sits below the price.",
                "category": "company",
                "datetime": 1787137606,
                "headline": "Moderna Stock Jumps 150%, Best Day Ever On Cancer Vaccine Win"
              },
              {
                "id": 141254576,
                "url": "https://finnhub.io/api/news?id=1b836e838eaedf2d33b698a7cbfdb205c0e53ea7218647fd41929187bc0ac8b2",
                "image": "https://image.cnbcfm.com/api/v1/image/108351559-17871495241787149521-47861858063-1080pnbcnews.jpg?v=1787149523&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "CNBC’s Annika Kim Constantino reports on Moderna after its experimental skin cancer vaccine with Merck showed success in a late-stage trial.",
                "category": "company",
                "datetime": 1787135546,
                "headline": "Moderna stock nearly doubles on new cancer vaccine results"
              },
              {
                "id": 141253626,
                "url": "https://finnhub.io/api/news?id=197e8c0d9d262c1b0887027aa7719c9b3fc37a633e76ff3691b8fb96e449251b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Estee-Lauder-Store-Sign-Close-up--Estee-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.",
                "category": "company",
                "datetime": 1787134092,
                "headline": "Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday"
              },
              {
                "id": 141253313,
                "url": "https://finnhub.io/api/news?id=2e1130e90380ab9807504bf240b0038a51a19924cdacc932dd13f4834b335bfb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688769969/image_1688769969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.",
                "category": "company",
                "datetime": 1787131330,
                "headline": "AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?"
              },
              {
                "id": 141254577,
                "url": "https://finnhub.io/api/news?id=15264f55e016123df482408b04b326a707d997d600a5b117bf24f202d6274f6e",
                "image": "https://image.cnbcfm.com/api/v1/image/108351449-17871406841787140679-47859846134-1080pnbcnews.jpg?v=1787140683&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of an experimental personalized cancer vaccine that showed positive initial results in its first-ever late-stage trial, how the mRNA-based shot in combination with Merck’s immunotherapy Keytruda could serve as a new treatment option for melanoma, and more.",
                "category": "company",
                "datetime": 1787127335,
                "headline": "'An increased ability to be disease-free': Moderna CEO & Merck's Dr. Li on skin cancer vaccine trial"
              },
              {
                "id": 141253685,
                "url": "https://finnhub.io/api/news?id=922be37f07b47e91ea7174e9e92f34c1bfd15cd3aaf2c1dd8ea5d241a7a28c8d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Cancer---Heart-Shape-To-Represent-Medica.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck and Moderna report positive Phase 3 results for their mRNA cancer therapy combined with Keytruda in melanoma patients.",
                "category": "company",
                "datetime": 1787125256,
                "headline": "Merck and Moderna Release Landmark Personalized Cancer Therapy Trial Success, Stocks Soar"
              },
              {
                "id": 141254578,
                "url": "https://finnhub.io/api/news?id=615b4c20357dff6843cbc3cc73731ea6690e792f225c7e9861c0c27946818b87",
                "image": "https://image.cnbcfm.com/api/v1/image/108222303-1762434766877-gettyimages-2235744008-CANADA_BIOMANUFACTURING.jpeg?v=1782501052&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRK",
                "summary": "These are the stocks posting the largest moves premarket.",
                "category": "company",
                "datetime": 1787124760,
                "headline": "Stocks making the biggest moves premarket: Moderna, Lowe's, Estee Lauder & more"
              },
              {
                "id": 141253686,
                "url": "https://finnhub.io/api/news?id=9e7199bb26b9b774c5f3aeda95d80147d50f2723df8632b6435bb1be0163af9a",
                "image": "",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ:MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with",
                "category": "company",
                "datetime": 1787122047,
                "headline": "Merck And Moderna Announce Topline Results From The Phase 3 Interpath-001 Trial Evaluating Adjuvant Treatment With Intismeran Autogene In Combination With KEYTRUDA In Patients With Completely Resected Stage IIB-IV Melanoma; At A Pre-specified Interim Analysis, Intismeran In Combination With KEYTRUDA As Adjuvant Therapy Demonstrated Statistically Significant And Clinically Meaningful Improvements In RFS And DMFS Compared To KEYTRUDA Alone"
              },
              {
                "id": 141246754,
                "url": "https://finnhub.io/api/news?id=c403cfdc8e76b95c2c482fae3fa9b3d407ffa166cf0ae935a0f4797898d64f03",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1787071206,
                "headline": "Which dow jones stocks are moving on Tuesday?"
              },
              {
                "id": 141247070,
                "url": "https://finnhub.io/api/news?id=b1f4f9103ba4ea73808da7ba801f781b9c6bab74333c738278cbe9332470efae",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/18/Experts-Warn-On-Costly-Attacks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "CNBC's Halftime Report Final Trades: Weiss picks Cisco, Lebenthal chooses Cheniere, Saccocia recommends iShares US Utilities ETF, Terranova names Merck.",
                "category": "company",
                "datetime": 1787040894,
                "headline": "Cisco, Merck, Cheniere Energy And More: CNBC’s ‘Final Trades’"
              },
              {
                "id": 141244204,
                "url": "https://finnhub.io/api/news?id=e6bf7b78e031bbcb468b8823cda499b666ece9ead74075c85b9647263cd0d6bf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255337276/image_2255337276.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787020480,
                "headline": "5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now"
              },
              {
                "id": 141242298,
                "url": "https://finnhub.io/api/news?id=6c674bf3153c4c112b1c368a5a3d8d5c53ce0cb6ca09bafc6aeb63dd260d5f92",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2062658519/image_2062658519.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "SCHD is beating SPY amid volatility—see top-performing, undervalued dividend stocks, YTD leaders, and 10%+ upside potential.",
                "category": "company",
                "datetime": 1786996527,
                "headline": "The Hidden Winners Inside SCHD - August 2026"
              },
              {
                "id": 141240002,
                "url": "https://finnhub.io/api/news?id=ec0668889a4c1c71892f8037054930e2b4ad337fa2c786bae0c8ac483da2e41c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1786993806,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 141230802,
                "url": "https://finnhub.io/api/news?id=f27678b5a5ecd46e15edc0e77302ec2996e442f4cec8d95c252a55f426f58c84",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/472209441/image_472209441.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "Preview key market catalysts: Walmart, Target & Home Depot earnings, Fed minutes, PMI data, and S&P 500 changes.",
                "category": "company",
                "datetime": 1786861929,
                "headline": "Wall Street Week Ahead"
              },
              {
                "id": 141224230,
                "url": "https://finnhub.io/api/news?id=378bd32677ead84815eb5c03e6e3830b56b7b1e398114ef6ed1b456b3a5bcb95",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503342678/image_1503342678.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRK",
                "summary": "A SWAN income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning. Read how to build one here.",
                "category": "company",
                "datetime": 1786781400,
                "headline": "How To Invest $100,000 In A Retiree's SWAN Income Portfolio"
              },
              {
                "id": 141218195,
                "url": "https://finnhub.io/api/news?id=e68255156e4e105f214c444853c71b963923217bcaf673dbe5944afb9e19188f",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "A large exercise of company stock options by Jennifer Zachary, EVP at Merck & Co (NYSE:MRK) was disclosed in a new SEC filing on August 13, as part of an insider exercise.\nWhat Happened: Zachary, EVP at Merck &",
                "category": "company",
                "datetime": 1786705480,
                "headline": "Jennifer Zachary At Merck & Co Capitalizes: Options Exercised, Resulting In $1.33M"
              },
              {
                "id": 141210900,
                "url": "https://finnhub.io/api/news?id=714f3049974d05781568e54aeb73177aa98de4466863007fedd00cdb53fec5a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across […]",
                "category": "company",
                "datetime": 1786657568,
                "headline": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine"
              },
              {
                "id": 141210901,
                "url": "https://finnhub.io/api/news?id=c33bf4e538c947db085978ac00055bb8a4acef0bef0138fee0ca9da27720ab80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck’s pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the Fair Value for...",
                "category": "company",
                "datetime": 1786651670,
                "headline": "Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress"
              },
              {
                "id": 141209435,
                "url": "https://finnhub.io/api/news?id=fe477b528bf195ac7f12746c8dac3b63378d9c099e9f5ada24d4772eab51eb48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRK",
                "summary": "Merck stock has almost doubled investors' money over the past five years, yet there is a clear split between valuation tools. A Discounted Cash Flow (DCF) estimate points to a sizeable gap to intrinsic value, while market based multiples suggest the shares are already pricing in a lot of optimism. Merck has returned 99.7% over five years, which puts recent gains in focus as investors weigh how much future growth is already reflected in the price. Ongoing investment in oncology and new...",
                "category": "company",
                "datetime": 1786648261,
                "headline": "Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook"
              },
              {
                "id": 141208986,
                "url": "https://finnhub.io/api/news?id=d809f45966630d8a19facd36d00cdb710b4ed6f03d04f981ead22bea0fe9d02d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRK",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1786648206,
                "headline": "Stay informed with the top movers within the dow jones index on Thursday."
              },
              {
                "id": 141212002,
                "url": "https://finnhub.io/api/news?id=a49ada6d588f5b407986d9ef1ad7a1f31ced0d59ecaac489c1e8fbc96a55ba7e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/Benzinga-Quick-Spark.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRK",
                "summary": "Dell, JPMorgan and Merck hit all-time highs on Thursday. Michael Dell's wealth surged, making him the fifth richest person globally.",
                "category": "company",
                "datetime": 1786641589,
                "headline": "QUICK SPARK: Dell, JPMorgan, Merck All Mark New All-Time Highs"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 237,
            "discarded_article_count": 222
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.5,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(21.2%→6.5%)；跌縮量(近10日4日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 10270050,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 8580340,
              "avg_vol_20": 11238525,
              "avg_vol_30": 10270050,
              "range_pct_10": 0.06523391160017193,
              "range_pct_20": 0.19355951948313727,
              "range_pct_30": 0.21214842014038965,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8354720765721686,
              "dist_to_20d_high": 0.07781028549579388,
              "down_shrink_days": 4,
              "breakout_level_20d": 156.92,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.30749185667752443
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 2.6190309847950393,
              "turnoverUsdM": 1077.10713824211,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.MRK",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 137.13,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.2,
            "take_profit_price": 151.9455,
            "target_multiplier": 1.6,
            "technical_strength": 1.38,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.2380619695900785,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.MRK",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 64.29,
    "atr": {
      "atr": 3.79,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.62
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -21.71
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1375
    },
    "kdj": {
      "d": 39.95,
      "j": 0.79,
      "k": 26.9,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 35.76
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 77860989,
      "recentSlope": -2543021.1,
      "previousSlope": 1943280
    },
    "rsi": 43.34,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 155.9599,
      "position": "SAR喺價上",
      "distancePct": 7.77,
      "previousTrend": "下降"
    },
    "ma50": 135.6728,
    "macd": {
      "macd": 3.965091298010293,
      "trend": "中性偏多",
      "signal": 5.11444210665771,
      "histogram": -1.1493508086474167
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 147.9656,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.67,
      "score": 2,
      "avgVolume": 11088331,
      "currentVolume": 7443211
    },
    "derived": {
      "ma20": 147.35,
      "ma50": 135.6728,
      "prevClose": 147.53,
      "avgVolume10": 8461901,
      "avgVolume20": 11088331,
      "changePercent": -1.91,
      "avgVolumeForScore": 11088331
    },
    "ma_cross": {
      "ma20": 147.35,
      "ma50": 135.6728,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 146.7605,
      "prevMa50": 135.3486,
      "spreadPct": 8.61,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 134.6824,
      "upper": 160.0176,
      "position": "中間"
    },
    "rsi_short": 24.53,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.67
    }
  }
}

{
  "close": 144.71,
  "volume": 7443211,
  "changePercent": -1.91
}